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Background: Long-term clinical outcomes have been similar for endovascular and open repair of
abdominal aortic aneurysm (AAA), increasing the importance of comparing costeeffectiveness.
Methods: We compared data to two years from a multicenter randomized trial of 881 patients. Quality-
adjusted life years (QALYs) were calculated from EQ-5D questionnaires. Healthcare utilization data were
obtained from patients and from national VA and Medicare sources. VA costs were obtained using
methods previously developed by the VA Health Economics Resource Center. Costs for non-VA care were
determined from Medicare or billing data.
Results: Mean life-years were 1.78 in the endovascular and 1.74 in the open repair group (P ¼ 0.29), and
mean QALYs were 1.462 in the endovascular and 1.461 in the open group (P ¼ 0.78). Although graft costs
were higher in the endovascular group ($14,052 vs. $1363; P < 0.001), length of stay was shorter (5.0 vs.
10.5 days; P < 0.001), resulting in lower cost of AAA repair hospitalization in the endovascular group
($37,068 vs. $42,970; P ¼ 0.04). Costs remained lower after 2 years in the endovascular group but the
difference was no longer signiﬁcant ($5019; 95% CI: $16,720 to $4928; P ¼ 0.35). The probability that
endovascular repair was both more effective and less costly was 70.9% for life-years and 51.4% for QALYs.
Interpretation: Endovascular repair is a cost-effective alternative to open repair in the US VA healthcare
system for at least the ﬁrst two years.
Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
Several randomized trials have compared endovascular with
open repair for abdominal aortic aneurysm (AAA). These trials have
generally reported reduced peri-operative mortality with endo-
vascular repair, but mid- and long-term outcomes have been
similar for the two procedures.1e3 The need is therefore increased
for accurate comparison of costs, particularly in view of the high
cost of endovascular grafts.1,4,5
The US Department of Veterans Affairs (VA) Open Versus
Endovascular Repair (OVER) trial reported a comparison of clinicaltions on this paper, please go
iveness of open versus endo-
of a multicenter randomized
lar Surgery 2012;56:901e10.
.
ppendix.
r Ltd on behalf of European Societyoutcomes of the two procedures at two years after randomization.3
We summarize here, for the same two-year period, total healthcare
costs and comparative costeeffectiveness of elective open and
endovascular repair of AAA in the VA OVER trial.Methods
Patients and clinical outcomes
Methodsandtwo-yearclinicaloutcomeswerereportedpreviously.3
In summary, eligible patients had AAA with (1) a maximum external
diameter of at least 5.0 cm, (2) an associated iliac aneurysm with
amaximumdiameter of at least 3.0 cm, or (3) amaximumdiameter of
at least 4.5 cm plus either rapid enlargement or saccular morphology.
Patients also required to be candidates for both procedures, and were
excluded if they had previous abdominal aortic surgery, needed urgent
repair, or were unable or unwilling to give informed consent or follow
the protocol. Follow-up visits were scheduled 1month after aneurysm
repair, 6 and 12 months after enrollment, then yearly. All follow-up
visits after endovascular repair included a computed tomogram andfor Vascular Surgery.
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a computed tomogram at one year was speciﬁed.
The primary outcomes of this costeeffectiveness analysis were
mean total healthcare cost per life year and per quality-adjusted life
year (QALY). This report, like the clinical report,3 includes follow-up
data to two years after randomization as of October 15, 2008. 881
patients were randomized between October 2002 and April 2008 at
42 VA medical centers, 444 to endovascular repair and 437 to open
repair. Mean follow-up was 1.8 years, and 80% of patients had either
completed two years of follow-up or died before two years. As
described in the clinical paper,3 peri-operative mortality (30 days or
inpatient)was lower for endovascular repair (0.5% vs. 3.0%;P¼ 0.004),
but there was no statistically signiﬁcant difference in mortality at 2
years (7.0% vs. 9.8%, P ¼ 0.13). Nor were there statistically signiﬁcant
differences at two years between the two groups in major morbidity,
procedure failure, secondary therapeutic procedures, aneurysm-
related hospitalizations, or health-related quality of life.3Assessment of utilization and costs
All healthcare costs were included in this analysis and were
adjusted to 2008 US dollars with the Consumer Price Index. Costs for
the hospitalizations during which the AAA repair operation was
performedwereobtained fromtheVADecisionSupport System(DSS)
National Data Extracts.6 In the DSS, costs are compiled from inter-
mediate products that make up the encounter, such as a radiologic
test, a day in award, or a 15-min block of time in anoperating room.A
hospital stay is divided into segments based on the bed section, such
as a medical care or surgical ward or a long-term care unit.
Within each bed section, DSS allocates costs among six mutually
exclusive categories: surgery, nursing, laboratory, radiology, phar-
macy, and ‘other’. The ‘surgery’ cost category could thus be included
whether or not a patient is on the surgery bed section, and encom-
passespre-operative care, the operating suite and the recovery room
on the day of surgery. ‘Nursing’ includes the operating costs of
regular acute-care wards and long-term care units, excluding
physician costs. The category ‘other’ includes daily physician costs,
ward clerks, respiratory therapy, dietetics, social work, etc. Each of
these six categories includes ﬁxed direct costs (those directly
attributable to that categorybut incurred regardless of the volumeof
services provided) and ﬁxed indirect costs (overhead departments
such as housekeeping, engineering, and administration), allocated
by formulae based on intermediate product use. Graft components
used for eachpatientwere recordedonOVER study forms, andprices
were obtained from the VA’s National Patient Prosthetics Database.
Other VA utilization data, including other hospital stays,
outpatient visits, contract care, and outpatient medications
acquired from VA, were obtained from the VA Medical SAS Inpa-
tient and Outpatient Datasets, which capture all utilization from
the electronic record system of local VA medical centers,7,8 and
from the Fee Basis ﬁles, which report care provided to VA patients
by contract providers outside of VA facilities.9
For VA utilization other than the hospitalization for the AAA
procedure, costs were obtained from the VA Health Economics
Resource Center (HERC) average cost datasets.10e12 These are more
directly comparable to the Medicare costing used for non-VA
healthcare utilization than is the DSS method.
Non-VA healthcare utilization was obtained from Medicare
claims data (available for 67% of the patient-months in the study
period) and from patient self-reported data veriﬁed with billing
data from the facilities where care was received. Costs were esti-
mated by multiplying the healthcare charges in the Medicare
claims or billing data by the hospital-speciﬁc cost-to-charge ratios
obtained from cost reports submitted to Medicare annually.13Assessment of effectiveness
Measures of effectiveness were life-years from randomization
and quality-adjusted life years (QALYs), which incorporate health-
related quality of life and medical outcomes into a single
measure.13 Health-related quality of life was assessed using the EQ-
5D questionnaire (EuroQol, Rotterdam, the Netherlands). EQ-5D
index scores obtained at baseline, six months, and annually were
converted into utility weights.14 The utility weights were connected
with straight lines to construct the quality-adjusted survival curve.
QALYs were computed from the area under the curve using the
trapezoid rule.
Analysis
Cost and effectiveness (measured in life-years and QALYs) was
compared on an intention-to-treat basis, regardless of the occur-
rence or type of the actual AAA repair. We discounted costs, life-
years, and QALYs at 3% per year starting with the date of
randomization.13
Bootstrap methods were used to examine the distribution of the
incremental cost (i.e., mean total costs of the endovascular group
minus mean total costs of the open repair group) and incremental
effectiveness (i.e., mean life-years or QALYs for the endovascular
group minus mean life-years or QALYs for the open repair group)
across regions of the costeeffectiveness plane.5,15
Results
The mean cost of the hospital admission for AAA repair was
lower for the endovascular repair group at $37,068 vs. $42,970 for
the open repair group (difference $5901, 95% CI: $12,135
to $821; P ¼ 0.04) (Table 1). This was despite the surgical
procedure itself being more expensive in the endovascular group
($23,618 vs. $11,594; P < 0.001) due to the high costs of the grafts
($14,052 vs. $1363; P < 0.001). However, the endovascular group
had shorter stays in the hospital (mean 5.0 vs. 10.5 days; P < 0.001)
and intensive care unit (mean 1.9 vs. 5.6 days; P < 0.001). Other
costs of the AAA repair hospitalizationwere therefore higher in the
open group, including nursing, pharmacy, laboratory, and ﬁxed
direct and indirect costs (as shown for nursing in Table 1).
From hospital discharge to two-years, costs were similar
between the two groups (Table 2). Total mean costs after two years
were $75,325 in the endovascular group and $80,344 in the open
group, a non-signiﬁcant difference of $5019 (95% CI: $16,720 to
$4928; P ¼ 0.35).
Costeeffectiveness analysis
Mean life-years during the study period were 1.78 for the
endovascular group and 1.74 for the open group (difference 0.04,
95% CI 0.03 to 0.09; P ¼ 0.29). Health-related quality of life as
measured by the EQ-5D did not differ signiﬁcantly between the two
groups at baseline, 6months, one year, or two years. Combining this
quality of life information with life-years, the endovascular group
had a mean of 1.462 quality-adjusted life year (QALYs) while the
open group had 1.461 QALYs (difference adjusting for baseline EQ-
5D score: 0.006, 95% CI: 0.038 to 0.052; P ¼ 0.78). Endovascular
repair was the dominant strategy with lower costs and more life-
years, so we did not calculate an incremental costeeffectiveness
ratio (i.e., the cost per year of life saved).
To characterize the precision of our costeeffectiveness esti-
mates, a bootstrap analysis conducted by 2000 samplings (with
replacement) of the 881 observations from trial participants is
plotted in Fig. 1. Measuring effectiveness in life-years, the
Table 1
Costs of hospitalization for abdominal aortic aneurysm repair.
Item Endovascular repair (N ¼ 444) Open repair (N ¼ 437) Cost difference (95% CI) P-value
Surgery bed section 35,695 40,169 4474 (10,265 to 67) 0.04
Nursing cost category 6193 16,007 9815 (12,857 to 7833) <0.001
Intensive care units 2349 6466 4118 (5757 to 3089) <0.001
Wards 830 1317 486 (766 to 233) 0.0005
Other (recovery room, stepdown, etc) 412 1274 862 (1372 to 575) <0.001
Fixed indirect total 2482 6579 4097 (5615 to 3206) <0.001
Fixed direct total 119 371 252 (444 to 156) 0.0002
Surgery cost category 23,618 11,594 12,024 (10,852 to 13,187) <0.001
Operating room 3219 3902 683 (1070 to 280) 0.001
Surgical implants 14,052 1363 12,689 (12,227 to 13,099) <0.001
Anesthesia 1184 1528 344 (526 to 158) 0.0003
Other 447 415 32 (181 to e286) 0.79
Fixed indirect total 4389 3982 407 (105 to e907) 0.11
Fixed direct total 327 405 77 (129 to 22) 0.005
Radiology cost category 1597 1253 343 (0 to e717) 0.06
Laboratory cost category 796 2034 1238 (1612 to 958) <0.001
Pharmacy cost category 895 2733 1838 (3446 to 1291) <0.001
Other cost category 2597 6548 3951 (5254 to 3003) <0.001
Other bed sections 1373 2802 1429 (2804 to 50) 0.04
Total cost 37,068 42,970 5901 (12,135 to 821) 0.04
Total cost, Median (IQR) 32,094 (26,306, 40,038) 30,506 (21,785, 42,768)
IQR ¼ interquartile range.
Costs are in US dollars and are means except when median speciﬁed.
See Methods for explanation of items.
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effective than open repair was 70.9% (Fig. 1(A)). Measured in QALYs,
this probability dropped to 51.4% (Fig. 1(B)). The proportions of
observations from the bootstrap analyses below the diagonal lines
indicate the observations that would favor endovascular repair if
the decisionmaker werewilling to pay $50,000 or $100,000 per life
year or QALY. From these observations, if willing to pay $50,000,
endovascular repair is preferred in 88.1% of observations using life-
years and 83.4% using QALYs. If willing to pay $100,000, the
proportions are 90.4% and 83.3%, respectively.
Discussion
We observed no signiﬁcant differences in survival, quality of life,
or costs after two years between endovascular and open repair of
AAA in this multicenter randomized trial. The hospitalization for
AAA repair was less expensive in the endovascular repair group dueTable 2
Healthcare costs to 2 years after randomization in US dollars.
Endovascular repair (N ¼ 444)
Before AAA repair
Total 2292
Median (IQR) 576(102, 1425)
AAA repair in year 1
Total, per randomized patient 37,068
Median (IQR) 32,094 (26,306, 40,038)
Discharge after AAA repair to 30 days
Total 2344
Median (IQR) 1085 (337, 2115)
30 days to 1 year
Total 18,348
Median (IQR) 9090 (5,799, 16,895)
Total at 1 year 60,053
Median (IQR) 47,705 (37,315, 64,809)
Total, 1 year to 2 year 15,272
Median (IQR) 6511 (2,772, 16,322)
Total at 2 years 75,325
Median (IQR) 59,782 (43,666, 82,568)
AAA ¼ abdominal aortic aneurysm; VA ¼ Department of Veterans Affairs; IQR ¼ interqu
Costs are in US dollars and are means except when median (IQR) is speciﬁed.
See Methods for explanation.to shorter hospital and intensive care stay and despite the high cost
of the endovascular grafts. Apart from the hospital admission for
the AAA procedure, two-year costs were similar between the two
groups.
Most previous randomized trials and observational studies have
found endovascular repair to be the more expensive strategy
despite shorter hospital and intensive care stay.1,4,5 In the Dutch
Randomized Endovascular Aneurysm Management (DREAM) trial,
endovascular repair cost signiﬁcantly more than open repair after
one year (V18,179 vs. V13,886) despite shorter hospital and
intensive care stay.5 Similarly, in the United Kingdom Endovascular
Aneurysm Repair Trial 1 (EVAR 1), a trend toward higher cost with
endovascular compared with open repair ($19,698 vs. $17,917)
became statistically signiﬁcant when AAA-related costs to amedian
6.0 years were included ($23,153 vs. $18,586).1 Endovascular repair
also led to higher hospital charges than open repair in a 20% sample
of US 2001 hospital admissions ($50,346 vs. $47,009).16Open repair (N ¼ 437) Cost difference (95% CI) P-value
2064 227 (646 to 1198) 0.63
582(89, 1317)
42,338 5269 (11,591 to 518) 0.03
30,077 (21,684, 42,694)
2700 355 (1272e554) 0.44
409 (132, 1051)
16,149 2199 (2536 to 6435) 0.33
6183 (3,163, 13,718)
63,252 3199 (12,939 to 5054) 0.48
43,633 (30,782, 65,479)
17,091 1820 (6105 to 2425) 0.42
5810 (2,356, 16,002)
80,344 5019 (16,720 to 4928) 0.35
55,153 (38,262, 85,369)
artile range.
Figure 1. Costeeffectiveness planes. Bootstrap replications showing the differences in costs and/or life-years (LYs) (A) or quality-adjusted life year (QALYs) (B) on the coste
effectiveness plane between patients randomized to endovascular or open repair at 2 years of follow-up. The large dot indicates the point estimate from the study.
F.A. Lederle, K.T. Stroupe / European Journal of Vascular and Endovascular Surgery 44 (2012) 543e548546Possible explanations for the difference between our ﬁndings
and these earlier reports include: (1) timing e we entered
patients 2002e2007, compared with 1999e2003 for EVAR-1 and
DREAM and 2001 for the US sample, and expenses per inpatient
day increased by more than 50% in the US from 1999 to 2007;17(2) Lower costs for hospital days, but similar costs for endo-
vascular grafts, in Europe compared with the US;1,5 and (3), the
VA cost accounting methods used in our study may have
captured hospitalization costs more thoroughly than previous
studies.
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costs distributes among both groups some costs that might seem to
apply to only one group, such as disposable supplies and items
bought for repeated use. Second, some pre-operative costs were
not included because patients had to be candidates for both
procedures prior to randomization, which required some evalua-
tion beforehand. Third, there were a few protocol-driven practices
that could distort costs, such as the required computed tomogram
one year after open repair. Fourth, quality of life data were not
collected in the ﬁrst 6 months, during which a transient difference
favoring endovascular repair has been reported.18
Fifth, our study was conducted at VA medical centers using VA
accounting methods, included only 5 women, and beneﬁtted
from VA pricing for endovascular grafts. Our results therefore
may not apply to other settings, particularly those in which
endovascular grafts costs are substantially different from the
mean $14,052 per patient we observed. Finally, we reported all
healthcare costs, rather than only those related to AAA repair.
While this might be considered a limitation, assessment of all
costs is the preferred method recommended by guidelines.19
Furthermore, the majority of costs in this 2-year analysis were
clearly intervention-related.
Our ﬁndings show that endovascular repair is a cost-effective
alternative to open repair in the US VA healthcare system for at
least the ﬁrst two years.Appendix
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